License agreement for SlimBiome® Medical in the US
RNS & Investor News
Appointment of Cambridge Commodities as UK distributor
01 June 2020
Non-exclusive distribution agreement with ProBiotix Health Ltd
OptiBiotix Health plc (AIM:OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announces that its wholly-owned subsidiary, ProBiotix Health Ltd. ("ProBiotix"), has entered into a non-exclusive distribution agreement with Cambridge Commodities Ltd ("CCL") for the distribution of LPLDL® and CholBiome®x3 in the UK.
The agreement grants CCL a non-exclusive licence to distribute ProBiotix's specialty ingredient LPLDL®as well as the finished dietary supplement CholBiome®x3 for cholesterol and blood pressure reduction.
CCL is one of the UK's leading specialty ingredients suppliers. The agreement extends the commercial reach of LPLDL® into new application areas where CCL has specific sector expertise, such as food and beverage, sports nutrition, health & wellbeing and beauty. The agreement builds on OptiBiotix's existing relationship with CCL (RNS: 28 January 2020) which led to the successful launch of SlimBiome® in Holland and Barrett.
CCL is a supplier of nutritional ingredients to major UK retailers, and supplement companies. CCL has 10 sales offices which cover the UK, Europe, USA and South Africa with a multi-million pound annual turnover (https://www.cambridgecommodities.com/home.htm). LPLDL® and CholBiome®x3, are fully patented products and of natural origin developed by experts to provide documented significant reductions of LDL-cholesterol, as well as blood pressure levels which combined reduce the risk of Cardiovascular Disease multiplicatively. The products will be purchased from ProBiotix and distributed by CCL in UK. The agreement is based on minimum order quantities.
ProBiotix was created to develop science based healthy lactic acid bacteria called probiotics to reduce cardiovascular risk. Independent clinical studies have shown LPLDL®probiotic can reduce key cardiovascular bio-markers such as total cholesterol, LDL (bad) cholesterol, and blood pressure by up to 36.7%, 13.9% and 5.1% respectively. Since launching its CholBiome® products containing LPLDL® in May 2017, ProBiotix has signed over 30 agreements and its products are now commercialised in approximately 43 countries. LPLDL® was designated Generally Recognized As Safe ("GRAS") by an independent Expert GRAS Panel in the United States in February 2019, which extends its applications from use as a supplement to use as a functional ingredient in a wide range of food, dairy, and beverage products in the USA.
Mikkel Hvid-Hansen, Commercial Director of ProBiotix Health Ltd., commented: "We are pleased to announce the signing of the distribution agreement with CCL. We chose them due to their leading market position and expertise in commercialising value added speciality ingredients like LPLDL® and CholBiome®x3 to major UK retailers and supplement companies. We believe working with CCL, and similar partners around the world, provides the best opportunity to expand the range of applications for LPLDL® and CholBiome®x3 to a wide variety of industry sectors. This agreement is another step in our low cost approach to growing revenues by building manufacturing, formulation/application and distribution partnerships which provide revenues across the whole value chain in multiple industry sectors."
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.
For further information, please contact:
|OptiBiotix Health plc||www.optibiotix.com|
|Stephen O'Hara, Chief Executive||Contact via Walbrook below|
|Cairn Financial Advisers LLP (NOMAD)||Tel: 020 7213 0880|
|Liam Murray / Jo Turner / Ludovico Lazzaretti|
|finnCap (Broker)||Tel: 020 7220 0500|
|Geoff Nash / Kate Bannatyne (Corporate Finance)|
|Camille Gochez (Corporate Broking)|
|Walbrook PR Ltd||Mob: 07876 741 001|
About OptiBiotix - www.optibiotix.com
OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.
OptiBiotix has an extensive R&D program working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.
OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes.
OptiBiotix Health secures significant exclusive licence agreement for OptiBiome
Stephen O'Hara | 01 Apr 2020